Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia

This study is testing a new type of CAR-T cell therapy for people with B-cell blood cancers (like leukemia or lymphoma) that have come back or stopped responding to treatment. Instead of taking cells out of a patient's body, this therapy delivers genetic instructions using a special particle to create cancer-fighting immune cells inside the body. **You may be eligible if...** - You have been diagnosed with B-cell leukemia or B-cell lymphoma (confirmed by tissue testing) - Your cancer has relapsed (come back) or is refractory (stopped responding) to standard treatments - You have exhausted standard treatment options or are unable to tolerate them - Your cancer meets specific criteria for relapsed/refractory status (such as relapsing within 6 months of remission, or failing multiple treatment attempts) **You may NOT be eligible if...** - Your cancer is currently in remission - You have serious organ problems that would make this treatment unsafe - You have uncontrolled active infections - You are not willing to comply with study requirements Talk to your doctor to see if this trial is right for you.